Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 1/20 | 0.49 |
| ▸ | SRC | P12931 | 1/20 | 0.49 |
| ▸ | IGF1R | P08069 | 3/20 | 0.49 |
| ▸ | TNK2 | Q07912 | 9/20 | 0.49 |
| ▸ | BTK | Q06187 | 7/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6955025 | 0.89 | IGF1R (0.61) | IGF1RTNK2BTK | |
| SCHEMBL6940141 | 0.84 | RAF1 (0.69) | RAF1SRCIGF1RTNK2BTK | |
| SCHEMBL593544 | 0.79 | FGFR1 (0.66) | IGF1RTNK2 | |
| SCHEMBL595398 | 0.79 | IGF1R (0.56) | RAF1SRCIGF1RTNK2 | |
| SCHEMBL13962636 | 0.78 | TNK2 (0.63) | IGF1RTNK2 | |
| SCHEMBL12165238 | 0.76 | FGFR1 (0.55) | IGF1RTNK2 | |
| SCHEMBL6942535 | 0.76 | RAF1 (0.74) | RAF1SRCIGF1RTNK2BTK | |
| SCHEMBL593347 | 0.76 | TNK2 (0.63) | RAF1SRCIGF1RTNK2 | |
| SCHEMBL593345 | 0.76 | TNK2 (0.63) | RAF1SRCIGF1RTNK2 | |
| SCHEMBL12593625 | 0.73 | TNK2 (0.65) | IGF1RTNK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7923555-B2 | Fused bicyclic mTor inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-7923555-B2 | Fused bicyclic mTor inhibitors | OSI PHARMACEUTICALS, INC. (US) | 2011-04-12 | — | — | US | disclosed |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | OSI PHARMACEUTICALS, INC. | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163468-A1 | Fused Bicyclic mTor Inhibitors | MTOR, RICTOR, MAPKAP1 | RAF1 260/4885SRC 294/4885IGF1R 1033/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.